Omega-3 fatty acid + Celecoxib for Breast Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores how two anti-inflammatory treatments—fish oil capsules and celecoxib (also known as Celebrex)—affect breast cancer associated with pregnancy. Researchers aim to determine if these treatments can reduce inflammation and the cancer’s potential to spread. Participants will join one of three groups: observation only, fish oil, or celecoxib. Those diagnosed with breast cancer and planning surgery at least a week from diagnosis might be suitable candidates. As an Early Phase 1 trial, this research focuses on understanding how these treatments work in people, offering participants a chance to contribute to groundbreaking research.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop all current medications, but if you are taking more than one 1000mg fish oil capsule daily or celecoxib, you must stop at least 1 week before starting the study. If you are randomized to the control group, you must abstain from fish oil or celecoxib during the study.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that omega-3 fatty acids, commonly found in fish oil, are usually safe for people to take. Studies have explored their potential to lower breast cancer risk, and they generally have few side effects. However, more research is needed to confirm their effectiveness in reducing cancer risk.
Celecoxib, a COX-2 inhibitor, has undergone testing for safety in breast cancer patients. Research indicates it is generally safe, with no major increase in serious side effects compared to a placebo. However, it may not always prevent breast cancer from returning.
Early studies suggest that both omega-3 fatty acids and celecoxib are safe for people, with few side effects. Still, consulting a healthcare provider before starting any new treatments is important.12345Why are researchers excited about this trial's treatments?
Researchers are excited about these treatments because they offer novel approaches to tackling breast cancer. Celecoxib, a nonsteroidal anti-inflammatory drug, is being explored for its potential anti-cancer properties, targeting inflammation-related pathways that could inhibit tumor growth. On the other hand, omega-3 fatty acids, commonly found in fish oil, are being investigated for their ability to reduce inflammation and possibly slow cancer progression by altering cell membrane composition and function. These treatments are unique because they aim to exploit anti-inflammatory mechanisms, which are different from the traditional chemotherapy and hormone therapies typically used for breast cancer.
What evidence suggests that this trial's treatments could be effective for pregnancy associated breast cancer?
Research has shown that omega-3 fatty acids, which participants in this trial may receive, might help fight breast cancer by reducing inflammation and slowing cancer cell growth. Some studies have found that fish oil, rich in omega-3s, can lower the risk of breast cancer and slow cancer cell development. Omega-3s have also improved certain health indicators in individuals undergoing or after breast cancer treatment.
Celecoxib, another treatment option in this trial, has shown mixed results in treating breast cancer. Some studies suggest it might stop cancer cells from growing by blocking certain enzymes and cutting off the blood supply to tumors. However, other research found no significant difference in survival rates between patients taking celecoxib and those who did not.13467Who Is on the Research Team?
Virginia Borges, MD, MSc
Principal Investigator
University of Colorado, Denver
Are You a Good Fit for This Trial?
This trial is for breast cancer patients with normal organ function, an ECOG performance status of 0-1, and a platelet count within the normal range. They must be willing to avoid fish oil or celecoxib if assigned to the control group and agree to surgery at least one week after diagnosis. Exclusions include history of stroke or heart disease, current high-dose fish oil or celecoxib use unless they stop prior to the study, pregnancy intending to continue, autoimmune conditions, chronic steroid use, psychiatric issues affecting compliance, previous cancers except breast cancer treated over 5 years ago.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either omega-3 fatty acid or celecoxib until the morning of surgery
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Celecoxib
- Omega-3 fatty acid
Trial Overview
The study tests whether short-term treatment with anti-inflammatory drugs (fish oil capsules and COX-2 inhibitor celecoxib) can reduce inflammation and immune suppression in pregnancy-associated breast cancer (PABC), potentially decreasing its ability to spread. The goal is also to gather data on biomarkers affected by these interventions.
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
Active Control
Patients receive celecoxib by mouth twice a day until the morning of surgery.
Patients receive omega-3 fatty acid by mouth everyday until the morning of surgery.
Patients undergo observation.
Celecoxib is already approved in United States, European Union, Canada for the following indications:
- Pain relief
- Inflammation
- Osteoarthritis
- Rheumatoid arthritis
- Menstrual cramps
- Colorectal polyps prevention
- Symptomatic relief in osteoarthritis
- Symptomatic relief in rheumatoid arthritis
- Ankylosing spondylitis
- Acute pain
- Primary dysmenorrhea
- Adenomatous polyposis coli
- Symptomatic relief of osteoarthritis
- Symptomatic relief of rheumatoid arthritis
- Ankylosing spondylitis
- Acute pain
- Primary dysmenorrhea
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Colorado, Denver
Lead Sponsor
Published Research Related to This Trial
Citations
Celecoxib in breast cancer prevention and therapy - PMC
Thus, celecoxib shows an anticancer activity and seems to be effective in anticancer treatment. Bocca et al assessed the antiproliferative activity of celecoxib ...
Celecoxib may be a viable treatment option for breast ...
Celecoxib has shown efficacy in preclinical studies of breast cancer and also as a chemopreventive agent in epidemiological investigations.
Celecoxib in Treating Women With Metastatic or Recurrent ...
RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by stopping blood flow to the tumor.
Effect of Celecoxib vs Placebo as Adjuvant Therapy on ...
Disease-free survival events were reported for 487 patients (19%): 18% for those receiving celecoxib vs 19% for those receiving placebo, a ...
Celecoxib Safe, but Not Effective, for Breast Cancer
There were also no differences in OS between the two groups, with 5-year OS of 90% in the celecoxib group and 91% in the placebo group. ER ...
The Efficacy and Safety of Celecoxib in Addition ...
Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status ...
7.
cancerresearchuk.org
cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-celecoxib-for-women-with-breast-cancerA trial looking at celecoxib for women with breast cancer ...
The trial team found that taking celecoxib for 2 years didn't stop HER2 negative breast cancer coming back.
Other People Viewed
By Subject
By Trial
Related Searches
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.